SCHEMBL6542543

SCHEMBL6542543

CN(C)CCOc1cc(NS(=O)(=O)c2ccc(F)c(Cl)c2)ccc1Cl

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.56
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
ALDH1A1 P00352 4/20 0.56
PKM P14618 2/20 0.56
TSHR P16473 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
PABPC1 P11940 1/20 0.55
MAPT P10636 4/20 0.53
HTT P42858 2/20 0.53
THRB P10828 2/20 0.53
FABP4 P15090 1/20 0.50
XBP1 P17861 2/20 0.49
HPGD P15428 2/20 0.49
POLB P06746 1/20 0.49
GAA P10253 1/20 0.47
UTS2R Q9UKP6 4/20 0.46
CACNA1H O95180 2/20 0.44
CACNA1B Q00975 2/20 0.44
EGFR P00533 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6541903 0.88 LMNA (0.51) LMNAMEN1KMT2AALDH1A1PKM
SCHEMBL6542083 0.85 UTS2R (0.53) LMNAMEN1KMT2AALDH1A1PKM
SCHEMBL6542791 0.85 LMNA (0.63) LMNAMEN1KMT2AALDH1A1PKM
SCHEMBL6542669 0.84 UTS2R (0.53) LMNAMEN1KMT2AALDH1A1PKM
SCHEMBL6186717 0.84 CACNA1B (0.54) LMNAMEN1KMT2AALDH1A1MAPT
SCHEMBL6540525 0.83 VCAM1 (0.50) LMNAMEN1KMT2AALDH1A1MAPT
SCHEMBL6174632 0.82 CACNA1B (0.53) LMNAALDH1A1MAPTHTTFABP4
SCHEMBL6542118 0.82 UTS2R (0.57) LMNAMEN1KMT2AALDH1A1PKM
SCHEMBL6542141 0.82 UTS2R (0.49) LMNAMEN1KMT2AALDH1A1MAPT
SCHEMBL6542032 0.81 HTR6 (0.61) LMNAMEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1248607-A4 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-10-06 EP claimed
US-20030100580-A1 Urotensin-II receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-05-29 US claimed
EP-1248607-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-10-16 EP claimed
WO-2001045694-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-28 WO claimed
EP-1248607-A4 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-10-06 EP disclosed
US-20030100580-A1 Urotensin-II receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-05-29 US disclosed
EP-1248607-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-10-16 EP disclosed
WO-2001045694-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100580-A1 Urotensin-II receptor antagonists UTS2R, TMPRSS4, PLAUR LMNA 4591/4885MEN1 4143/4885KMT2A 3232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.